Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Melanoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1NSCLC 1Gastrointestinal Stromal Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Cervical Cancer Metastatic 1Carcinoma, Transitional Cell 1BRCA-Mutated Breast Carcinoma 1Advanced Solid Tumor 1

Interventions

toripalimab 2Injections 2ulixertinib 1tislelizumab 1spartalizumab 1lenvatinib 1famitinib 1erdafitinib 1camrelizumab 1Oxaliplatin 1Leucovorin 1Irinotecan 1Gemcitabine 1Docetaxel 1Cisplatin 1Capecitabine 15-fluorouridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Solid Tumor × famitinib × Clear all
NCT05208177 2025-08-22

A Study of SHR-1802 in Patients With Advanced Solid Tumor

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Terminated
25 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡